TrialTitleStudy Record DetailPhaseSponsor/ Collaborator
Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDSNCT02706899I & IISeattle Genetics, Inc.
A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML PatientsNCT02614560I & IISeattle Genetics, Inc.
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (CASCADE)NCT02785900IIISeattle Genetics, Inc.
A Safety Study of SGN-CD33A in AML PatientsNCT01902329ISeattle Genetics, Inc.
A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AMLNCT02326584ISeattle Genetics, Inc.

Last Editorial Review: June 19, 2017